Member access

4-Traders Homepage  >  Shares  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG (BAYN)

231
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Bayer AG : EARNINGS FORECAST TABLE : Bayer 4Q 2012

02/22/2013 | 08:32am US/Eastern

FRANKFURT--The following is a summary of analysts' forecasts for Bayer AG (BAYN.XE) fourth-quarter results, based on a poll of 10 analysts conducted by Dow Jones Newswires (figures in million euros, EPS, dividend and target price in euro, according to IFRS). Earnings figures are scheduled to be released February 28.

=== 
 
                          EBITDA   EBITDA   EBIT    EBIT 
4th Quarter        Sales    adj.    rep.    adj.  reported 
 
AVERAGE            9,726   1,811   1,585   1,092     901 
Prev. Year         9,191   1,541   1,415     844     629 
+/- in %            +5.8     +18     +12     +29     +43 
 
MEDIAN             9,743   1,821   1,585   1,102     841 
Maximum            9,905   1,893   1,633   1,191   1,053 
Minimum            9,536   1,707   1,536     970     808 
Amount (a)            10      10       2       6       5 
 
Baader Bank        9,725   1,839      --      --      -- 
Credit Suisse      9,793   1,831      --   1,191     966 
Deutsche Bank      9,559   1,869      --   1,135   1,053 
Equinet            9,760   1,820      --      --     838 
Exane BNP Paribas  9,611   1,817      --     970      -- 
J.P. Morgan        9,883   1,821   1,633   1,125      -- 
Nomura             9,536   1,707      --   1,078     808 
UBS                9,840   1,760      --      --      -- 
 
 
 
                  Net attrib.             EPS 
4th Quarter         income      EPS      core 
 
AVERAGE              468       0.55      1.06 
Prev. Year           397       0.48      0.97 
+/- in %             +18        +15      +9.3 
 
MEDIAN               494       0.53      1.06 
Maximum              549       0.66      1.12 
Minimum              332       0.46      1.00 
Amount (a)             8          6        10 
 
Baader Bank          542         --      1.02 
Credit Suisse        466       0.56      1.05 
Deutsche Bank        538         --      1.05 
Equinet               --       0.50      1.08 
Exane BNP Paribas    332         --      1.09 
J.P. Morgan          521       0.63      1.06 
Nomura               413       0.50      1.00 
UBS                   --         --      1.03 
 
 
 
               Target price  Rating                 DPS 2012 
 
AVERAGE               77.27  positive 6     AVERAGE     1.84 
Prev. Quarter         67.20  neutral  3     Prev. Year  1.65 
+/- in %                +15  negative 1     +/- in %     +11 
 
MEDIAN                75.00                 MEDIAN      1.83 
Maximum               90.00                 Maximum     1.94 
Minimum               65.60                 Minimum     1.77 
Amount                    9                 Amount         6 
 
Baader Bank           65.60  Hold                         -- 
Barclays              66.00  Underweight                1.81 
Citigroup             90.00  Buy                        1.85 
Commerzbank           90.00  Buy                          -- 
Credit Suisse         82.80  Outperform                 1.94 
Deutsche Bank         86.00  Buy                        1.77 
Equinet               75.00  Accumulate                 1.85 
Exane BNP Paribas     73.00  Neutral                    1.80 
J.P. Morgan              --  Overweight                   -- 
UBS                   67.00  Neutral                      -- 
=== 

Year-earlier figures are as reported by the company.

(a) Including anonymous estimates from two more institutes.

DJG/voi 

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

React to this article
Latest news on BAYER AG
2d ago BAYER : to divest equine assets to Merial; Divestiture includes Legend /Hyonate ..
3d agoDJBayer Plans to Sell Equine-Health Products to Sanofi Unit
3d ago BAYER : to divest equine assets to Merial -- Divestiture includes Legend® /Hyona..
5d ago NATCO PHARMA : Apex court quashes bayer's plea on nexavar licence
12/12 BAYER : strives to improve lives with innovative products
12/09DJMerck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update
12/09DJMerck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update
12/09DJMerck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 4th Update
12/09 BAYER : and DNDi Sign First Agreement to Develop an Innovative Oral Treatment fo..
12/09 BAYER : Inauguration of the TDI-plant Dormagen -- Adress by Dr. Marijn Dekkers -..
Dynamic quotes  
ON
| OFF